English
Chinese (Simplified)
French
Portuguese
Spanish
German
Spread The News
Forward to a Friend
Print This Story
Write a Comment
More Industry Headlines
Will the EU medical device approval process get tougher? Expert analyst talks about a new potential challenge for the industry.
Prior authorization schemes don't save taxpayers money Congressional Budget Office scores health care programs, including imaging.
Q&A with a U.S. Army biomed To celebrate Healthcare Technology Management Week, here's a story of one biomed's unique journey.
Maryland governor signs breast density law Maryland joins the growing list of states to enact density notification laws.
GE Healthcare unveils technology for imaging metal implants First-time software can create clear images despite metal.
FDA approves radiopharmaceutical to treat advanced prostate cancer Radioactive therapeutic agent can spare healthy tissue.
Monarch Medical PET Services removes CEO Gary Moyers named interim CEO.
Will the Angelina Jolie mastectomy test change cancer screening? The actress sheds awareness on new genetic screening tool for breast cancer.
What technologies should we be using for mammography? A new study fills in the gaps in digital breast mammography.
New contrast agent could last longer than traditional dyes Researchers say they have found a cheaper, more effective dye.
Varian backs radiosurgery vs. traditional surgery study
A Varian spokeswoman told DOTmed News the Sunnyvale, Calif-based company will kick in some funds and provide other help to support the study's goal of accruing 420 patients over a five-year period. As of June, 45 centers had qualified to participate in the phase III trial, the company said.
Empty Trailers Wanted - Full Service Dealer
Top Dollar Paid for empty trailers. Call our Transportation Specialist for a Quote today -- 212-558-6600 Ext. 250 
The NCI-financed project is being run by the Alliance for Clinical Trials in Oncology, a one-year-old collaboration among three cancer research organizations: the American College of Surgeons Oncology Group, Cancer and Leukemia Group B and North Central Cancer Treatment Group.
Formally known as ACOSOG Z4099/RTOG 1021, the study seeks to compare whole-body stereotactic radiosurgery, which uses higher doses of radiation in fewer fractions, against sublobar resection, the surgical removal of part of the lobe of the lung, for high-risk patients with non-small cell lung cancer whose cancer is operable.
"To date, there have not been any prospective, randomized trials to compare the efficacy and toxicity of surgery to radiosurgery for high-risk operable early-stage lung cancer patients," Kolleen Kennedy, president of Varian's oncology systems business, said in a statement. "We anticipate that this trial could yield very useful information for making treatment decisions about these types of cases."
According to a "talking points" document hosted on ACOSOG's website, an earlier study involving radiosurgery performed on patients with medically inoperable early-stage lung cancer achieved 56 percent survival rates after three years, double the reported rates for conventional radiation therapy. The researchers are hoping for higher survival rates in the high-risk operable population involved in the current study.
Varian makes the TrueBeam STx and the Trilogy Tx radiosurgery devices.
Interested in Medical Industry News?
Subscribe to DOTmed's weekly news email and always be informed.
Click here, it takes just 30 seconds.
You Must Be Logged In To Post A CommentRegisterRegistration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now! |
|
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2013 DOTmed.com, Inc.
ALL RIGHTS RESERVED
